Zontivity (vorapaxar), a new class of drugs called protease-activated receptor-1 (PAR-1) antagonist, has now been approved by the FDA to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart attack or blockages in the arteries to the legs. Available in tablet form, Zontivity is described as “an anti-platelet agent, designed to decrease the tendency of platelets to clump together to form a blood clot. By doing so, the drug lowers the danger of heart attack and stroke.” In fact, a clinical trial involving 25,000 participants showed that when added to other anti-platlet agents such as aspirin and clopidogel, Zontivity also “reduced the rate of a combined endpoint of heart attack, stroke, cardiovascular death, and urgent procedures to improve blood flow to the heart (coronary revascularization).
“Zontivity has been found to reduce risk of heart attack on people who have had them, or who have peripheral arterial disease from 9.5%-7.9% over a 3-year period,” noted Ellis Unger, M.D., director of the Office of Drug Evaluation I in the FDA’s Center for Drug Evaluation and Research.
To learn more readers can contact the FDA information line at 888 Info-FDA.